BRPI0607140A2 - composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios - Google Patents

composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios

Info

Publication number: BRPI0607140A2
Authority: BR; Brazil
Prior art keywords: compound; cells; stimulating; carbohydrate; pharmaceutically acceptable
Prior art date: 2005-02-18

Application number

BRPI0607140-6A

Other languages

English (en)

Portuguese (pt)

Inventor

Claude Coquelet

Charles Mioskowski

Alain Wagner

Original Assignee

Innodia Inc

Centre Nat Rech Scient Cnrs

Univ Pasteur Strasbourg I

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-18

Filing date

2006-02-17

Publication date

2009-08-11

2006-02-17 Application filed by Innodia Inc, Centre Nat Rech Scient Cnrs, Univ Pasteur Strasbourg I filed Critical Innodia Inc

2009-08-11 Publication of BRPI0607140A2 publication Critical patent/BRPI0607140A2/pt

Links

150000001875 compounds Chemical class 0.000 title abstract 6
238000000034 method Methods 0.000 title abstract 6
150000001720 carbohydrates Chemical class 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
150000003839 salts Chemical class 0.000 title abstract 3
230000004936 stimulating effect Effects 0.000 title abstract 3
241000124008 Mammalia Species 0.000 title abstract 2
230000023852 carbohydrate metabolic process Effects 0.000 title abstract 2
150000002596 lactones Chemical class 0.000 title abstract 2
230000037356 lipid metabolism Effects 0.000 title abstract 2
239000000651 prodrug Substances 0.000 title abstract 2
229940002612 prodrug Drugs 0.000 title abstract 2
210000004027 cell Anatomy 0.000 title 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
210000001789 adipocyte Anatomy 0.000 title 1
239000008103 glucose Substances 0.000 title 1
230000003914 insulin secretion Effects 0.000 title 1
210000000663 muscle cell Anatomy 0.000 title 1
OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical class C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 abstract 1
206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000001280 Prediabetic State Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
208000020450 carbohydrate metabolism disease Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 abstract 1
208000017745 inborn carbohydrate metabolic disease Diseases 0.000 abstract 1
230000002473 insulinotropic effect Effects 0.000 abstract 1
230000002503 metabolic effect Effects 0.000 abstract 1
201000009104 prediabetes syndrome Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BRPI0607140-6A 2005-02-18 2006-02-17 composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios BRPI0607140A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US65441305P	2005-02-18	2005-02-18
PCT/IB2006/001758 WO2006117696A2 (en)	2005-02-18	2006-02-17	Diastereoisomers of 4-hydroxyisoleucine and uses thereof

Publications (1)

Publication Number	Publication Date
BRPI0607140A2 true BRPI0607140A2 (pt)	2009-08-11

Family

ID=37086084

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0607140-6A BRPI0607140A2 (pt)	2005-02-18	2006-02-17	composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios

Country Status (8)

Country	Link
EP (1)	EP1853552A2 (de)
JP (1)	JP2008530198A (de)
CN (1)	CN101128418A (de)
AU (1)	AU2006242851A1 (de)
BR (1)	BRPI0607140A2 (de)
CA (1)	CA2598491A1 (de)
MX (1)	MX2007009985A (de)
WO (1)	WO2006117696A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1874287A2 (de) *	2005-03-22	2008-01-09	Innodia Inc.	Verbindungen und zusammensetzungen zur verwendung bei der vorbeugung und behandlung von fettleibigkeit und damit zusammenhängenden syndromen
WO2008154743A1 (en) *	2007-06-19	2008-12-24	Innodia Inc.	Methods for the synthesis of 4-hydroxyisoleucine, stereoisomers and analogs thereof
US20110136911A1 (en) *	2007-12-20	2011-06-09	The Feinstein Institute For Medical Research	Treatment of sepsis and inhibition of mif by d-t4
AU2016342027B2 (en)	2015-10-23	2021-05-13	Navitor Pharmaceuticals, Inc.	Modulators of Sestrin-GATOR2 interaction and uses thereof
PL3615019T3 (pl)	2017-04-26	2026-01-19	Navitor Pharmaceuticals, Inc.	Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie
EP3870158A4 (de)	2018-10-24	2022-08-10	Navitor Pharmaceuticals, Inc.	Polymorphe verbindungen und verwendungen davon
US11723890B2 (en)	2019-11-01	2023-08-15	Navitor Pharmaceuticals, Inc.	Methods of treatment using an mTORC1 modulator
CN112089710B (zh) *	2020-08-07	2022-04-01	郑州大学	4-羟基异亮氨酸在制备抗肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2797767B1 (fr) *	1999-08-27	2002-06-14	Centre Nat Rech Scient	Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
CA2543498A1 (en) *	2003-10-27	2005-05-06	Innodia Inc.	Use of hydroxylated amino acids for treating diabetes
EP1657236A1 (de) *	2004-11-10	2006-05-17	Centre National De La Recherche Scientifique (Cnrs)	Verfahren zur Herstellung von Diastereoisomeren von 4-Hydroxyisoleucin

2006
- 2006-02-17 EP EP06765601A patent/EP1853552A2/de not_active Withdrawn
- 2006-02-17 CN CNA2006800050682A patent/CN101128418A/zh active Pending
- 2006-02-17 AU AU2006242851A patent/AU2006242851A1/en not_active Abandoned
- 2006-02-17 WO PCT/IB2006/001758 patent/WO2006117696A2/en not_active Ceased
- 2006-02-17 MX MX2007009985A patent/MX2007009985A/es not_active Application Discontinuation
- 2006-02-17 CA CA002598491A patent/CA2598491A1/en not_active Abandoned
- 2006-02-17 JP JP2007555732A patent/JP2008530198A/ja active Pending
- 2006-02-17 BR BRPI0607140-6A patent/BRPI0607140A2/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
MX2007009985A (es)	2008-03-11
WO2006117696A2 (en)	2006-11-09
CA2598491A1 (en)	2006-11-09
CN101128418A (zh)	2008-02-20
EP1853552A2 (de)	2007-11-14
AU2006242851A1 (en)	2006-11-09
JP2008530198A (ja)	2008-08-07
WO2006117696A3 (en)	2007-01-25

Similar Documents

Publication	Publication Date	Title
AU2020201457B2 (en)	2022-11-24	Compositions and methods for managing or improving bone disorders, cartilage disorders, or both
Li et al.	2012	Antihyperglycemic and antihyperlipidemic action of cinnamaldehyde in C57BLKS/J db/db mice
KR102396831B1 (ko)	2022-05-11	관절 건강을 위한 조성물 및 방법
Li et al.	2017	Gastrodin and isorhynchophylline synergistically inhibit MPP+-induced oxidative stress in SH-SY5Y cells by targeting ERK1/2 and GSK-3β pathways: involvement of Nrf2 nuclear translocation
UA100384C2 (en)	2012-12-25	Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
BRPI0607156A2 (pt)	2009-08-11	composto, composição farmacêutica, uso do composto, kit farmacêutico, método para estimular a absorção de glicose por células de músculo e/ou célula de adipócito e método para estimular a secreção pancreática
BR112013020620A2 (pt)	2016-10-04	análogos de ácido 4-hidroxibutírico
BRPI0718596B8 (pt)	2021-05-25	composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina
HRP20221106T1 (hr)	2022-11-25	Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
BRPI0507189A (pt)	2007-06-26	uso combinado de um agonista de glp-1 e compostos de gastrina
BRPI0607140A2 (pt)	2009-08-11	composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios
BRPI0516454A (pt)	2008-09-02	compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii
BR112015001056A2 (pt)	2017-06-27	composto, composição farmacêutica, métodos para o tratamento de distúrbios mediados pela aldosterona, para o tratamento de doença ou uma condição, para o tratamento da síndrome metabólica, para o tratamento de uma doença fisiológica ou patológica e para o tratamento da doença renal crônica, insuficiência renal ou nefropatia diabética
Rytting et al.	2005	Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells
Ohno et al.	2023	The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets
Kulkarni et al.	2014	Antidiabetic potential of Rourea minor (Gaertn.) root in streptozotocin—induced diabetic rats
BRPI0611550A2 (pt)	2009-01-13	uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto
Yousaf et al.	2012	Hypolipidemic effect of extra virgin olive oil in diabetic rats
US20230110065A1 (en)	2023-04-13	Combination of anethole trithione or its derivative, 4-oh-anethole trithione, with doxycycline or minocycline for the use thereof in the treatment of parkinson's disease
Adhikari et al.	2017	Comparative evaluation of antidiabetic activity of fresh juice and ethanolic extract of Sunderban mangrove Rhizophora mucronata Lam. leaves in animal model
Marshall et al.	2022	Role of Creatine Supplementation in Conditions Involving Mitochondrial Dysfunction: A Narrative Review. Nutrients 2022, 14, 529
Selvakumar et al.	2012	Neurotoxicity associated with neuroleptic haloperidol induced tardive dyskinesia in Albino mice: Protective role of morin
HK40079409A (en)	2023-04-21	Compositions and methods for joint health
BR112022007623A2 (pt)	2022-07-12	Composições para prevenir ou tratar doenças pulmonares obstrutivas crônicas (dpoc)
BR112021026561A2 (pt)	2022-02-15	Uso de uma composição farmacêutica na fabricação de um medicamento para a prevenção ou tratamento de doença hepática

Legal Events

Date	Code	Title	Description
2011-01-04	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2011-07-05	B11Y	Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired